International Agency for Research on Cancer (IARC) - Summaries & Evaluations

(Group 3)

For definition of Groups, see Preamble Evaluation.

Supplement 7: (1987) (p. 344)

CAS No.: 52-01-7
Chem. Abstr. Name: Pregn-4-ene-21-carboxylic acid,7-(acetylthio)-17-hydroxy-3-oxo-, g-lactone,(7a, 17a)

A. Evidence for carcinogenicity to humans (inadequate)

Cases of breast cancer have been reported in women who had used spironolactone. Four analytical studies, however, showed no consistent evidence of an assocation [ref: 1].

B. Evidence for carcinogenicity to animals (limited)

Spironolactone was tested by oral administration in two experiments in rats. Increased incidences of thyroid and testicular tumours were reported in one experiment but not in another experiment of longer duration with lower doses [ref: 1].

C. Other relevant data

No data were available to the Working Group.

Overall evaluation

Spironolactone is not classifiable as to its carcinogenicity to humans (Group 3).

For definition of the italicized terms, see Preamble Evaluation.

Subsequent evaluation: Vol. 79 (2001)

Also see previous evaluation: Vol. 24 (1980)


1. IARC Monographs, 24, 259-273, 1980


Last updated: 11 March 1998

    See Also:
       Toxicological Abbreviations
       Spironolactone  (IARC Summary & Evaluation, Volume 24, 1980)
       Spironolactone  (IARC Summary & Evaluation, Volume :79, 2001)